Orforglipron (LY3502970): Benefits, Dosing, Side Effects, & More

The global weight loss drug market has witness an explosive surge in both reach and profitability, with some estimates projecting it could reach $150 billion by 2035.

Semaglutide, Tirzepatide, and even the “King Kong” fat loss peptide known as Retatrutide only scratch the surface of what is possible through pharmacological means.

There are now numerous avenues through which we can improve upon existing weight loss agents.

More weight loss in a given period of time, fewer side effects, lower costs, and ease of administration are just a few examples off the top of my head.

I firmly believe Orforglipron, one of the newest GLP-1 receptor agonists under clinical investigation, will tackle the latter two.

It may not boast the most impressive results to date, but that sole criteria is not the reason why both physicians and investors alike are highly interested in this molecule.

This article will comprehensively cover what Orforglipron is, what has been observed in clinical trials to date, and the implications of its existence alongside its competitors.

What Is Orforglipron (LY3502970)?

(Source)

Orforglipron is a small molecule (i.e. non-peptide) GLP-1 receptor agonist that is manufactured by pharmaceutical company Eli Lilly that is currently under investigation in clinical trials for its use in treating Type 2 Diabetes and obesity.

(Technical note: Although Chugai Pharmaceutical Co., Ltd. originally discovered it, it was licensed by Eli Lilly in 2018)

As we will see later in this article, it is meant to be taken orally once and perhaps, multiple times per day.

But before I dive in deeper, let’s take a few steps back and bring in some relevant background information.

What Exactly Does Glucagon-Like Peptide-1 (GLP-1) Do Again?

I won’t bore you with the exhaustive molecular details of GLP-1, but here’s a short synopsis for people who are brand new to the Jay Campbell universe.

The GLP-1 hormone, which is naturally produced by your body primarily in intestinal mucosal L-cells (although it is also produced in other places), is responsible for regulating the metabolism of lipids and your blood sugar/glucose levels.

It exerts its biological effects by binding to the GLP-1 receptor (GLP-1R) within a cell, which stimulates the pancreas to release insulin that in turn keeps blood sugar levels within a given range, while also suppressing glucagon release at the same time.

When this happens, especially in gut and brain cells, numerous things happen: The brain receives a satiety signal that it has consumed an adequate amount of calories, and the contents of your stomach are emptied at a slower rate (i.e. gastric emptying).

This is also relevant for Type 2 diabetics who have insulin-resistant cells and ergo cannot produce enough insulin.

So we have four primary effects: Appetite suppression to lower food intake, delayed gastric emptying, inhibited glucagon release, and enhanced insulin secretion.

And now you understand the basis of how and why people suddenly feel full when using peptides like Semaglutide or Tirzepatide, which act as GLP-1 receptor agonists (GLP-1RAs) to mimic the effect of endogenous GLP-1.

Don’t We Already Have An Oral GLP-1 Receptor Agonist Peptide On The Market?

Anybody who has been paying close attention to the GLP-1 world will be quick to bring up Rybelsus, the brand name for oral Semaglutide that is currently FDA-approved solely for the treatment of Type 2 diabetes.

Rybelsus is a once-daily oral semaglutide tablet that is coformulated with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, an absorption enhancer that aids with oral delivery via absorption in the stomach.

This is important to mention in the context of therapeutic peptides, as any chemist already knows the many problems that exist with oral administration of peptides: Rapid enzymatic degradation in the intestinal tract, low permeability through the intestinal epithelial barrier to reach the bloodstream, and overall weak absorption.

And given the oral bioavailability of Rybelsus is lower than 1%, you can see how notoriously difficult this challenge is for drug manufacturers.

But the problems don’t stop there, as discussed in a 2020 paper where Orforglipron was synthesized and evaluated:

“…the approved doses of oral semaglutide (brand name Rybelsus) do not achieve the higher drug exposures required to deliver equivalent glucose and body weight–lowering efficacy observed with injectable semaglutide (brand name Ozempic).

Further, the dosing regimen for oral semaglutide is restrictive for patients since drug absorption is significantly affected by food and fluid in the stomach.

Specifically, the tablet must be administered after overnight fasting with a proscribed volume of water and at least 30 min before consumption of breakfast or other medicines.”

So you have the strict requirements about taking it fasted and not eating or drinking anything within 30 minutes of administration to avoid degradation, combined with not being competitive against the existing injectable formulations.

However, as you’ll see in the next section, there are other inherent advantages to having an oral small molecule GLP-1RA that is not peptide-like in nature.

So What’s The Point Of Making A NON-PEPTIDE Oral GLP-1RA?

First, let’s put the obvious conclusion upfront: A medication that is EASIER to take will always win out, all else being equal.

Let’s examine in greater detail what this means:

• Patients find it easier to adhere to a once-weekly medication vs. a once-daily medication for the convenience it offers
• Overwhemingly, patients will favor oral medications over injectable medications (even if the oral medication has to be taken more frequently, and despite injections being the highest-impact delivery system for peptides by a mile)
• Put simply, there are many reasons for this observation: Fear of injections, fears of injecting incorrectly, fear of side effects and pain associated with injections, cultural stigma associated with injections, and the hassle of having to learn how to properly reconstitute, dose, and store peptides

So the market desirability for something like Rybelsus is clear.

The picture gets a little more complicated when we compare our once-daily needle-free alternatives: An oral peptide like Rybelsus against an oral non-peptide like Orforglipron.

Although the product monograph for Rybelsus says it can be kept at room temperature in a dark and dry place, it still suffers from requiring cold chain storage much like other GLP-1 peptides that require refrigeration and plastic applications:

“Cold chain shipping involves maintaining a consistent temperature range from the point of manufacture to the point of use.

The primary reason why cold chain shipping is critical is to ensure that semaglutide retains its effectiveness until it reaches the patient.

Semaglutide is sensitive to temperature changes, and deviations from the recommended storage conditions can lead to a loss of potency, making the medication less or entirely ineffective.”

Orforglipron does not have these packaging requirements, giving it an edge over Rybelsus and other injectable GLP-1 peptides.

Orforglipron also has the benefit — as we’ll see later in this article — of being used without any restrictions whatsoever on water intake, food intake, or time of day around its administration.

Two points on the scoreboard so far!

A third point can be given to Orforglipron for the reason that large-scale small molecule synthesis is generally more favored over large-scale peptide synthesis.

Peptide synthesis, especially for injectable peptides, is typically more expensive and more technically difficult.

(A further extension on the advantages and disadvantages of small molecule vs. peptide synthesis can be found at the link above)

Orforglipron, due to its non-peptide nature, has the advantage of being more scalable by manufacturers, far cheaper to manufacture, and less prone to shortages. 

While we don’t know for sure what its price point will be upon FDA approval for Type 2 Diabetes treatment (currently estimated for 2026-2027), many experts speculate it will be much more affordable and thus more accessible than current injectable GLP-1 peptides on the market. 

Gone would be the days when someone’s financial status is the primary barrier to accessing these life-saving medications.

Four points in favor of Orforglipron!

Lastly, before we dive into the clinical trial results, I want to touch on one characteristic of Orforglipron that makes it unique.

An Interesting Property Of Orforglipron?

I’ll do my best to keep this section as simple as possible because the biochemistry can quickly become too complex for the non-science user.

The best way to understand why Orforglipron is arguably the most advanced agent among other oral non-peptide GLP-1RA candidates is to read this 2025 review paper.

When the GLP-1 hormone binds to the GLP-1R, two things happen: You have the engagement of selective G protein biased signaling, and you also have something called β-arrestin recruitment.

This leads to the production of cyclic AMP (cAMP) through adenylate cyclase, which triggers the desensitization and internalization of the receptor.

In the case of Orforglipron, it acts as a partial GLP-1RA that is selectively biased towards G protein activation (and thus a greater effect on cAMP activation) while minimizing both β-arrestin recruitment and receptor internalization.

Meaning it will activate one intracellular signaling pathway (G protein) over another one (β-arrestin).

Scientists believe this mechanism of action has several clinical implications:

• Less receptor desensitization (i.e. tachyphylaxis) in comparison to other GLP-1RAs
• Prolonged GLP1-R responsiveness
• Possible reduction of common gastrointestinal side effects such as nausea and vomiting in comparison to peptide-based GLP-1 RAs that engage G protein AND β-arrestin pathways

Add in an estimated oral bioavailability of 30-40% on top of a half-life of 29-49 hours, and you have a pharmacokinetic profile that supports once-a-day oral administration!

Health Benefits Observed In Clinical Trials

If you take a look at the slides Eli Lilly presented at this year’s American Diabetes Association (ADA) Investor Event, there is a LOT going on for Orforglipron right now:

And the slide above doesn’t even mention ACHIEVE-5, which will examine Orforglipron in combination with insulin versus placebo, or the other Phase III ATTAIN trials

(If you go to this link and type “Orforglipron”, you will see a current list of all active clinical trials for the compound being run by Eli Lilly)

So in order to avoid turning this article into a book, I will do the following:

• Briefly touch upon what was found in Phase I clinical trials
• Examine the Phase 2 clinical trial done in 2023 for overweight/obese adults in detail
• Examine the Phase 3 clinical trial (ACHIEVE-1) done in 2025 for patients with early Type 2 Diabetes

Let’s dive in!

Phase 1 Clinical Trials: Confirming Orforglipron’s Usefulness

The first trial I want to look at is a Phase 1A clinical trial published in the summer of 2023 that was blinded, placebo-controlled, and randomized.

Building off of the success in preclinical models where Orforglipron was shown to be pharmacologicaly equivalent to an injectable GLP-1RA with respect to insulin secretion and lowered food consumption, it was time to see if the results would hold up in humans.

But the first thing to do was see how safe and tolerable the drug would be in healthy adults.

The participants in question, ages 18-65, had to possess a healthy BMI (body mass index) and appropriate HbA1C readings (<6.5%).

Then the study was divided into two parts.

Part 1 had patients receiving either Orforglipron in a single-ascending dose (0.3 mg, 1 mg, 3 mg, 6mg) or  placebo

Part 2 had patients receiving either Orforglipron in a multiple-ascending dose fashion or placebo over 4 weeks, with doses escalated every week:

• 2 mg, 2 mg, 2 mg, 2 mg
• 2 mg, 4 mg, 6 mg, 6 mg
• 2 mg, 4 mg, 8 mg, 16 mg
• 2 mg, 5 mg, 12 mg, 24 mg

And here were the main takeaways…

Safety

• In Part 1, there were some instances of GI-related side effects (nausea, vomiting, headache) that generally corresponded with higher doses
• In Part 2, GI-related side effects (nausea, headache, constipation) were most common in both the initial dose and the final escalated dose
• There were no drug-related adverse events related to low blood sugar levels, cardiovascular events, or hepatic (liver) dysfunction
• In Part 2, there was an non-dose-dependent increase in pulse rate by 5-13 beats per minute on Day 28 in all groups taking Orforglipron relative to placebo, but no side effects of increased heart rate or tachycardia were reported

Pharmacokinetics

• In Part 1, the mean half-life of Orforglipron was observed to be 24.6-35.3 hours across the entire dosing range
• In Part 2, Orforglipron achieved peak concentration levels  in a dose-dependent manner, roughly 4.1-8.1 hours after dosing, with the mean half-life being 48-68 hours across the entire dosing range.

Weight Loss

• As the dose of Orforglipron increased, so did the observed weight loss at Day 28, 
• For doses greater than 6 mg, mean body weight reductions from baseline ranged between -4.8 kg and -5.4 kg.
• Patients on Orforglipron lost anywhere from -1.1 kg to -9.2 kg after 28 days of dosing, compared to +0.4 kg to -5.2 kg for patients on placebo

Miscellaneous

• Gastric emptying was delayed on Day 28
• Fasting glucose levels were decreased in Orforglipron-treated patients across Days 1-28

Factoring a side effect profile similar to existing GLP-1RAs, along with reductions in bodyweight and blood sugar, Orforglipron was seen as a viable once-daily oral treatment without requiring the restriction of food or water.

The second clinical trial, published around the same time by the same author, was a Phase 1B clinical trial that was also double-blinded and placebo-controlled.

This time, the participants were adults aged 18-70 who have had Type 2 Diabetes for at least 6 months prior to study enrollment, and for at least 3 months prior had been treated with Metformin OR diet and exercise alone.

Patients were subjected to one of six dosing arms for 12 weeks:

• Placebo
• 3 mg Orforglipron for Week 1, 6 mg for Week 2, 9 mg for the remainder 
• 3 mg Orforglipron for Week 1, 6 mg for Week 2, 12 mg for Week 3, 15 mg for the remainder 
• 3 mg Orforglipron for Week 1, 6 mg for Week 2, 12 mg for Week 3, 24 mg for the remainder
• 3 mg Orforglipron for Week 1, 6 mg for Week 2, 12 mg for Week 3, 21 mg for Week 4, 27 mg for the remainder
• 3 mg Orforglipron for Week 1, 6 mg for Week 2, 12 mg for Week 3, 21 mg for Week 4, 36 mg for Week 5, 45 mg for the remainder

And here is what they found…

Side Effects

• 76.5% of patients taking Orforglipron (39/51) experienced a drug-related adverse event, compared to 41.2% for placebo (7/17)
• The most common side effects were gastrointestinal (nausea, diarrhea, constipation, vomiting), which were too be expected
• The majority of gastrointestinal side effects occurred in the first week after dosing, i.e. it is just as important to get the starting dose right as how you escalate the dose (and how often)
• These side effects were most prevalent in the higher-dose Orforglipron groups, and were either mildly or moderately severe
• No significant changes in systolic or diastolic pressure were noted
• Pulse rate also went up by an average 4-10 beats/minute above baseline in Orforglipron groups when measured at Week 12, but like the prior study was also non-dose-dependent

Pharmacokinetics

• Orforglipron achieved peak concentration levels  in a dose-dependent manner within the 9 mg to 45 mg range in 4-8 hours post-administration
• Across all doses, the mean half-life ranged between 28.7 hours and 49.3 hours.

Other Health Benefits

• Except for 21 mg Orforglipron, attributable to a far smaller sample size, all other doses shows a significant reduction in bodyweight relative to baseline (when compared with placebo)
• -4 kg to -6 kg was observed in terms of the mean change in bodyweight at the end of Week 12. 
• All treatment groups reported lower hunger scores and food consumption, in addition to an increase in fullness and satiety.
• All Orforglipron groups saw significant HbA1C reductions compared to placebo (-1.38% for 9 mg, -1.34% for 15 mg, -1.09% for 21 mg, -1.34% for 27 mg, and -1.02% for 45 mg)
  • For context: Oral Semaglutide demonstrated -1.1% reduction in HbA1C and -2.3 kg mean body weight change over 26 weeks in the PIONEER-1 Phase 3 clinical trial
  • Danuglipron (twice-daily) had -1.25% mean reduction in HbA1C and as much as -7.2kg mean change in bodyweight after 28 days
  • Injectable GLP-1 peptides can achieve HbA1C reductions of -1.6% after 30 weeks

So just like the first Phase 1 clinical trial, the results were replicable in Orforglipron’s target population and demonstrated potential to be as viable as injectable GLP-1RAs while offering far more convenience.

Phase 2 Clinical Trial: What Can Orforglipron Do For Overweight/Obese Adults?

We now fast forward to the summer of 2023, where the “GZGI” Phase 2 clinical trial results have just been released to the world.

It’s one thing for Orforglipron to be a useful tool for diabetics seeking to restore insulin sensitivity.

But even back then, we were already at the point where the world was expecting fat loss peptides to deliver magic.

So this trial was critical for determining Orforglipron’s viability as a serious contender in the global weight loss drug market.

Enough story-telling — let’s see what this small molecule is capable of!

This double-blind, randomized trial looked at 272 participants using Orforglipron daily over the course of 36 weeks.

Participants (aged 18-75 years) had to be non-diabetic (HbA1C < 6.5%) and obese (BMI > 30) or overweight (BMI between 27 and 30) with at least one co-existing condition related to their weight.

And just to make sure things were kosher, weight had to be stable within the 3 months (i.e. no weight loss/gain of 5% or more) prior to being randomly assigned to a group

They were then divided into seven groups:

• Placebo
• 3 mg Orforglipron for Week 0, 6 mg Orforglipron for Week 8, 12 mg Orforglipron for Week 16 until the end of the study
• 3 mg Orforglipron for Week 0, 6 mg Orforglipron for Week 2, 8 mg Orforglipron for Week 3, 12 mg Orforglipron for Week 4, 24 mg Orforglipron for Week 5 until of the study
• 2 mg Orforglipron for Week 0, 3 mg Orforglipron for Week 1, 6 mg Orforglipron for Week 2, 8 mg Orforglipron for Week 3, 12 mg Orforglipron for Week 4, 24 mg Orforglipron for Week 5, 36 mg Orforglipron for Week 6 until the end of the study
• 3 mg Orforglipron for Week 0, 6 mg Orforglipron for Week 3, 12 mg Orforglipron for Week 6, 24 mg Orforglipron for Week 9, 36 mg Orforglipron for Week 12 until the end of the study
• 3 mg Orforglipron for Week 0, 6 mg Orforglipron for Week 2, 8 mg Orforglipron for Week 4, 12 mg Orforglipron for Week 6, 24 mg Orforglipron for Week 8, 36 mg Orforglipron for Week 10, 45 mg Orforglipron for Week 12 until the end of the study
• 2 mg Orforglipron for Week 0, 3 mg Orforglipron for Week 2, 6 mg Orforglipron for Week 4, 12 mg Orforglipron for Week 6, 24 mg Orforglipron for Week 8, 36 mg Orforglipron for Week 10, 45 mg Orforglipron for Week 12 until the end of the study

The results may not be at the level of Retatrutide, but they are nevertheless impressive for an oral tablet you take daily without special restructions:

To summarize the most important takeaway with regard to body weight reduction:

• At Week 26, mean weight loss relative to baseline ranged from -8.6% to -12.6% while placebo was at -2.0% (at Week 36 it was -9.4% to -14.7% while placebo was at -2.3%).
• When corrected for placebo, weight loss was -6.5% to -10.6% across all doses of Orforglipron at week 26 (and -7.1% to -12.3% at Week 36)
• Weight loss was dose-dependent and did not appear to plateau by Week 36

But let’s not forget about the relevant changes in cardiometabolic markers:

• Systolic blood pressure: Up to -10.5 mm Hg at Week 26 versus -3.6 mm Hg in placebo (and -10.5 mm Hg at Week 36 versus -1.8 mm Hg in placebo)
• Diastolic blood pressure: No meaningful changes in patients taking Orforglipron
• Pulse rate: +5.4 to +8.1 beats/minute Week 26 versus -2.3 beats/minute in placebo (and +5.9 to +7.8 beats/minute in Week 36 versus -2 beats/minute in placebo)
• Triglycerides: -3.6 to -12.8 mmol/L in Week 26 versus +2.1 mmol/L in placebo (and -7.2 to -14.1 mmol/L in Week 36 versus +0.8 mmol/L in placebo)
• Total cholesterol: -7.2 to -10.4 mmol/L in Week 26 versus -1.1 mmol/L in placebo (and -6.2 to -9.7 mmol/L in Week 36 versus -2.5 mmol/L in placebo)
• High-density lipoprotein (HDL) cholesterol: -2.3 to -6.8 mmol/L in Week 26 versus -2.4 mmol/L in placebo (and +0.5 to -1.6 mmol/L in Week 36 versus -3.6 mmol/L in placebo)
• Low-density lipoprotein (LDL) cholesterol: -7.7 to -11.7 mmol/L in Week 26 versus -1 mmol/L in placebo (and +-7.9 to -12.8 mmol/L in Week 36 versus -2.9 mmol/L in placebo)

And no discussion about Orforglipron in obesity would be complete without full transparency about its side effect profile:

• As expected, gastrointestinal events (nausea, vomiting, constipation) were the most common in Orforglipron patients and happened far more often compared to placebo
  • Frequency was higher in dosing groups starting with 3mg Orforglipron than with 2mg
  • Frequency was higher in dose escalations happening every 1-2 weeks than every 3 weeks
  • Similar to what’s been observed with injectable GLP-1RAs, they were mild to moderate in severity
  • They usually resolved on their own without requiring total discontinuation of Orforglipron
  • However, there was Orforglipron discontinuation in 10-17% of the participants across dosing groups, yet this incidence of treatment discontinuation has also been observed in prior Phase 2 trials of GLP-1RAs
• Patients in the Orforglipron group did not experience higher liver function values compared to patients in the placebo group
• As observed earlier, the mean pulse rate was higher in all patients taking Orforglipron and the highest change from the baseline occurred somewhere around Week 12

The end result?

Orforglipron has a safety profile similar to what is seen with the injectable GLP-1RAs, and the takeaway is relatively the same:

Start lower, and escalate the dose SLOWLY to reduce the incidence and severity of gastrointestinal events.

Nothing new under the sun.

And when you consider Semaglutide achieved a mean body weight reduction of -14.9% from baseline in 68 weeks (with a plateau), these results are nothing to scoff at.

Phase 3 Clinical Trial: What Can Orforglipron ACHIEVE For Type 2 Diabetes?

Going forward another two years, we find ourselves in the middle of June 2025 when the Phase 3 clinical trial results for Orforglipron in Type 2 diabetics (ACHIEVE-1) are released to the public. 

This double-blinded and placebo-controlled 40-week trial looked at 559 individuals with HbA1C readings of 7.0% to 9.5%, did not have any glucose-lowering medications 3 months prior to enrollment, and have failed to treat their diabetes with diet and exercise alone.

Participants were then divided into four once-daily dosing cohorts:

• Placebo
• 1 mg Orforglipron in Weeks 1-4, 3 mg Orforglipron in Weeks 5-40
• 1 mg Orforglipron in Weeks 1-4, 3 mg Orforglipron in Weeks 5-8, 6 mg Orforglipron in Weeks 9-12, 12 mg Orforglipron in Weeks 13-40
• 1 mg Orforglipron in Weeks 1-4, 3 mg Orforglipron in Weeks 5-8, 6 mg Orforglipron in Weeks 9-12, 12 mg Orforglipron in Weeks 13-16, 24 mg Orforglipron in Weeks 17-20, 36 mg Orforglipron in Weeks 21-40

And the results are summarized in the graphic below:

This can be a lot to take in, so let’s summarize the most important takeaways for Type 2 diabetics who have a vested interest in Orforglipron:

• Mean HbA1C decreases from baseline in Orforglipron ranged from -1.24% to -1.47%, compared to -0.41% with placebo (estimated mean difference from placebo would be -0.83% to -1.07%)
• Mean HbA1C levels were at 6.4% to 6.72% at the 40-week mark  in Orforglipron-taking patients, with 57% to 62% of those patients reaching a level of 6.5% or lower (compared to 15% on placebo) and therefore going from diabetic to pre-diabetic
  • 17-25% of participants using Orforglipron achieved HbA1C levels below 5.7% at the 40-week mark compared to 4% on placebo, therefore achieving normal blood glucose levels
• In graph D, Orforglipron uniformly led to superior reductions in glucose values before and 2 hours after the three main mealtimes of the day (breakfast, lunch, dinner) compared to placebo

And as for the secondary yet equally valuable changers in biomarkers:

• Mean reductions in bodyweight from baseline ranged from -4.5% to -7.6% in patients taking Orforglipron (versus -1.7% for placebo)
• Orforglipron had a larger proportion of people reaching relevant weight reduction targets (43-61% for ≥5% reduction, 15-30% for ≥10% reduction, 4-10% for ≥15% reduction) at the 40-week mark compared to placebo (17%, 6%, 1% respectively)
• Chart D in the figure above shows significant decreases in triglycerides, VLDL cholesterol, LDL cholesterol, and non-HDL cholesterol within the Orforglipron cohorts compared to placebo

Fortunately, the side effect profile appears to be favorable at the moment:

• Permanent stoppage of treatment due to adverse events occured in 4.4% to 7.8% of Orforglipron users, versus 1.4% of placebo users
• Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) were the most commonly reported
  • 2.8%, 2.2%, and 5.7% of patients taking Orforglipron (3 mg, 12 mg, 36 mg respectively) had to stop Orforglipron use due to a gastrointestinal event, compared to none for placebo
  • They were mostly observed during the dose-escalation period, and were mild to moderate in how severe they were
• A mean reduction in systolic blood pressure between -3.3 mm Hg to -5.7 mm Hg was observed in Orforglipron-using patients (compared to -1.2 mm Hg in placebo-using patients)
• Patients taking Orforglipron experienced a mean pulse rate increase of +2.2 to +4.8 beats/minute at the 40-week mark, compared to -0.9 beats/minute for placebo
• There were no incidents of severe hypoglycemia (i.e. blood sugar levels are too low), nor were any hepatic safety signals detected

So what can we take away from this trial? 

A couple of things…

The improvements in glycemic control were clearly meaningful, both significantly and clinically.

It was interesting to see how little of a difference 12 mg of Orforglipron made versus 36 mg of Orforglipron for relevant biomarkers in Type 2 diabetes.

The plateau in HbA1C levels at the 40-week mark seen for all doses of Orforglipron seems to suggest there is a limit to the glycemic response that can be achieved, which lines up with what’s been observed in prior studies on GLP-1RAs.

However, when it comes to weight loss, it does appear that higher doses do lead to more weight loss (albeit with the usual trade-off of more frequent/severe side effects).

But the highest mean reduction of body weight (-7.6% over 40 weeks) in diabetic patients pales compared to what was achieved in non-diabetic patients who are obese/overweight (-14.7% over 36 weeks).

Fortunately, it is well-known in the clinical literature that patients with Type 2 Diabetes do not respond as strongly to GLP-1RAs — especially the injectable peptides — in comparison to obese/overweight individuals without Type 2 Diabetes.

Final Thoughts On Orforglipron

There are so many positive characteristics of Orforglipron we can see in its ongoing Phase I-III clinical trials, validating its use as an agent for patients who are obese and/or diabetic.

Orforglipron can be taken by mouth due to its oral bioavailability, and without any restrictions on food, water, or medications taken before/after administration.

Its small molecule nature allows it to be synthesized more easily, manufactured for a lower cost, not require co-formulated absorption enhancers, and can be stored under simpler non-refrigerated conditions…

… features highly sought after in a scalable and mass-produced pharmaceutical drug.

Orforglipron’s ability to induce weight loss and suppress appetite is comparable to what is observed with Semaglutide (Wegovy), although the future will hopefully yield another similar drug that can compete with Tirzepatide and Retatrutide someday.

You also have the increases in insulin sensitivity and glucose disposal as evidenced by the drops in HbA1C readings.

This is in addition to the near-uniform improvements in various cardiometabolic markers.

Its safety profile is not only consistent with what we’ve seen with injectable peptide GLP-1RAs but also comparable.

There may be concerns around pulse rate elevations and discontinuations due to gastrointestinal effects, but I AM positive this is easily remedied with proper dose selection and escalation practices (combined with a fully optimized lifestyle).

Hopefully we see Orforglipron make it all the way to FDA approval, giving us our most accessible and cost-friendly weapon yet in our arsenal for treating the hundreds of chronic diseases tied with obesity.

While also setting the stage for what is possible for future small molecule oral GLP-1RAs undergoing development as we speak.

Where To Buy Orforglipron

But if you’re going to seek out Orforglipron through research chemical means, just know this:

Source quality and manufacturing standards matter.

I’ve personally vetted dozens of peptide suppliers, and I can tell you this without hesitation:

BioLongevity Labs sets the benchmark for authentic Khavinson-patented peptide bioregulators, with a ruthless focus on stringent third-party testing and top-notch customer service.

They consistently deliver the highest quality products, trusted by professionals for both personal and clinical use.

Whether you’re looking to elevate your performance or integrate these products into research applications, they are a reliable source you can count on.

BioLongevity Labs provides Orforglipron in the form of their newest product BioZapetite, where it comes in a 6 mg dose per capsule.

This will provide you with far greater flexibility in terms of your starting dose and how you escalate it.

I strongly recommend starting at 6 mg daily, increasing to 12 mg after 1-2 weeks but ONLY as needed.

(For me personally, this was enough to achieve a stable level of appetite suppression comparable to Tirzepatide without the side effect of nausea)

Only increase the dose further beyond this level every 2-3 weeks, based on your tolerance and desired level of appetite suppression.

This will help you avoid the gastrointestinal pitfalls faced by patients in the clinical trials.

Click here to get BioZapetite from BioLongevity Labs!

Use code JayC to get 15% off your order

I also invite you to join me and other like-minded biohackers in The Fully Optimized Health Private Membership Group.

This is where we dive deep into using peptides to optimize health, especially for those in their 30s and beyond. We’re also talking about cutting-edge biohacking and the latest and greatest in elite health optimization strategies.

And don’t forget to check out our other premium educational content dedicated to helping you fully optimize your health:

Peptides Demystified – the step-by-step, A-to-Z system for newbies desiring to master peptide use for the first time and forever.

The Ultimate GLP-1 Video Masterclass – how to PROPERLY utilize the world’s most powerful weight loss drugs for enhanced fat loss and overall longevity.

The Modern Woman’s Peptide Course – a must-have resource for any woman seeking to become more feminine, sexier, leaner, and healthier through the use of peptides.

Life Enhanced – Unlock the secrets to TOTAL Mind-Body-Spirit Optimization as Hunter Williams and I teach you how to live at the tip of the spear.

30 Days 2 Shredz – Reprogram Your Mind and Body for Maximum Fat Loss in Minimum Time with our Optimized Fasting Protocol

See you on the inside!